Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Consider This Model to Predict Myelofibrosis Survival

Haematologica; 2017 Jan; Rozovski, et al

Publish date:

A scoring system based on age and mutation status predicted survival in patients with primary myelofibrosis in a study involving 344 individuals.

Investigators screened participants—all of whom had primary myelofibrosis—for the presence of Janus kinase 2, calreticulin, and myeloproliferative leukemia mutations. Among the results:

  • Two-thirds of patients had Janus kinase 2V617F; 12% calreticulin, and 5% myeloproliferative leukemia mutations.
  • Patients with a favorable mutation status and those ≤65 years of age survived a median of 126 months.
  • Those with 1 risk factor had an intermediate survival duration.
  • Patients >65 years of age with an adverse mutation survived a median of only 35 months.

Citation:

Rozovski U, Verstovsek S, Manshouri T, et al. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 2017;102(1):79-84. doi:10.3324/haematol.2016.149765.

This Week's Must Reads